Richardo D. Parrondo, MD
Articles
Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL
Catherine C. Coombs, MD;Matthew S. Davids, MD, MMSc;Richardo D. Parrondo, MD ;Nicole Lamanna, MD;Alexey V. Danilov, MD, PhD
June 27th 2024Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.
Read More
Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024
Catherine C. Coombs, MD;Matthew S. Davids, MD, MMSc;Richardo D. Parrondo, MD ;Nicole Lamanna, MD;Alexey V. Danilov, MD, PhD
June 27th 2024Key opinion leaders are introduced and present a concise overview of the topics to be addressed.
Read More
Latest Updated Articles
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: July 2nd 2024 | Updated: July 5th 2024
Improving CAR T-Cell Therapy in Multiple Myeloma
Published: June 4th 2024 | Updated: July 5th 2024
Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer
Published: June 28th 2024 | Updated: July 5th 2024
Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer
Published: June 4th 2024 | Updated: July 5th 2024
Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma
Published: July 1st 2024 | Updated: July 5th 2024
TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers
